DoD Peer Reviewed Alzheimer’s Research Program, Accelerating Diagnostics Research Award | W81XWH 22 PRARP ADRA

FAQs: DoD PRARP Accelerating Diagnostics Research Award (ADRA)

1) What is the PRARP Accelerating Diagnostics Research Award (ADRA)?

The ADRA is a Department of Defense funding opportunity under the Peer Reviewed Alzheimer's Research Program (PRARP). It supports research designed to speed up the development of practical, clinically useful methods to diagnose or predict Alzheimer's disease and related dementias (AD/ADRD), particularly in populations whose risk may be linked to military service and/or traumatic brain injury (TBI).

2) What is the main goal of this award?

The central goal is to move promising diagnostic and prognostic factors beyond basic discovery and closer to real-world clinical use. The program is meant to close the gap between identifying a potentially relevant marker and delivering something providers can reliably use in practice.

3) What kinds of outcomes does the program care about?

The award emphasizes diagnostic and/or prognostic factors that are clearly tied to meaningful clinical endpoints for AD/ADRD after military service and/or TBI. Proposed factors should matter for detecting disease, staging disease, and/or forecasting disease course in ways that are relevant to clinical decision-making.

4) Is this award focused on Alzheimer's disease only, or also related dementias?

The opportunity includes Alzheimer's disease and related dementias (AD/ADRD), with AD/ADRD as the endpoint of interest for diagnostic and/or predictive performance.

5) How important is military service and/or TBI to the scope?

The opportunity is specifically framed around AD/ADRD in the context of people whose risk may be linked to military service and/or TBI. Proposed work should align with that context, including how the factor(s) relate to clinically meaningful AD/ADRD endpoints in these populations.

6) What types of research are encouraged under ADRA?

Research that advances robust diagnostic and/or prognostic factors and accelerates them toward clinical practice. This includes efforts that strengthen clinical relevance, improve readiness for translation, and demonstrate how a factor could be used in real clinical settings rather than remaining purely exploratory.

7) Are biomarkers the only allowable focus?

No. The scope allows investigation of both biomarkers and risk factors. Risk factors can be modifiable (potentially changeable through interventions or management) or non-modifiable (such as demographics or historical exposures), as long as they influence the likelihood of developing AD/ADRD and are evaluated for diagnostic or prognostic use.

8) Can a proposal focus on an interesting biomarker or risk factor by itself?

The opportunity indicates that it is not enough to propose an interesting biomarker or risk factor in isolation. The proposed factor(s) must be connected to meaningful clinical outcomes and must be described in terms of how they would be useful in practice for diagnosing, staging, or predicting AD/ADRD.

9) What does the program mean by "clinically useful"?

Applications are expected to explain the intent and purpose of the work in concrete terms and describe practical utility, including how results would change or inform clinical decision-making and disease management. Examples of clinical utility mentioned include screening, differential diagnosis, prognostic counseling, care planning, and monitoring, as well as what the information means for the person living with AD/ADRD in terms of planning, treatment pathways, support needs, and overall management.

10) What performance expectations are emphasized for diagnostic/prognostic factors?

The announcement highlights the need for credible potential to improve specificity and sensitivity for diagnosing and/or predicting AD/ADRD, with AD/ADRD as the endpoint. Applicants are expected to frame the work around performance and readiness for translation rather than purely exploratory aims.

11) Is preliminary data required?

Yes. Preliminary data are required, indicating this mechanism is intended for projects that already have an evidence base and are positioned to make a strong leap forward in validation, refinement, or demonstrated clinical relevance.

12) What does the opportunity say about validation?

The opportunity allows biomarker and risk factor validation activities, particularly when validation would broaden the populations in which the factor(s) can be applied and improve generalizability across diverse groups.

13) How is biomarker validation described in this opportunity?

Biomarker validation is described in practical measurement terms, including reproducibility, accuracy, precision, and sensitivity limits. This reflects an emphasis on dependable, scalable measurement, not only statistical association with disease.

14) Does the program address health equity or applicability across populations?

Yes. The announcement highlights equity and feasibility in real-world environments and notes that validation activities may be used to broaden applicability and improve generalizability across diverse groups.

15) What does the opportunity require regarding rural or resource-limited settings?

Applications must address how the proposed diagnostic/prognostic approach could function in rural or resource-limited settings, where access to specialty imaging, advanced laboratory infrastructure, or subspecialty clinicians may be constrained.

16) Are new clinical trials allowed under this mechanism?

No. New clinical trials are not allowed under this mechanism.

17) Can applicants use data or samples from existing clinical trials?

Yes. Researchers may leverage existing clinical trial resources by using previously collected data and/or human anatomical substances from an ongoing or completed clinical trial to conduct the proposed work, supporting faster progress without initiating a new interventional trial.

18) What type of funding mechanism is used (grant vs. cooperative agreement)?

Funding may be offered through grants and/or cooperative agreements.

19) Which organization administers this opportunity?

This is a discretionary DoD funding opportunity managed by the Department of the Army through USAMRAA.

20) What is the CFDA number associated with this opportunity?

The opportunity is listed under CFDA 12.420 (Science and Technology and other Research and Development).

21) Who is eligible to apply?

Eligibility is described as unrestricted (open to any type of entity), subject to any clarifications in the full eligibility text.

22) When was the opportunity posted and when did it close?

The opportunity was posted in April 2022 and had an original closing date in July 2022.

23) How many awards were expected?

The announcement anticipated making a small number of awards, expected to be two.

24) What should applicants emphasize when explaining their proposed work?

Applicants should spell out why the diagnostic/prognostic factor(s) would be useful in real clinical settings, how the results would inform provider decision-making and patient planning, and how the work accelerates translation to practice with attention to sensitivity/specificity and feasible implementation, including rural and resource-limited contexts.

25) What is the overall program theme in one sentence?

Advance and validate diagnostic and prognostic factors for AD/ADRD linked to military service and/or TBI, with preliminary evidence, a clear connection to meaningful clinical endpoints, and a strong focus on real-world feasibility and acceleration toward clinical use.